Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J. C. J. Stiekema"'
Publikováno v:
European Journal of Clinical Pharmacology. 41:245-250
Potential pharmacokinetic and pharmacodynamic interactions between a new low molecular weight heparinoid Org 10172 (bolus injection of 3250 anti-Xa units) and digoxin (0.25 mg once daily for 8 days) were studied in 6 healthy male volunteers using an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b7a4c5a20a037dabc4c01214dd6c688
https://doi.org/10.1007/bf00315437
https://doi.org/10.1007/bf00315437
Autor:
R. Dumas, Maximilien Kutnowski, F. Gregoire, I. Nikolic, F. Woitinas, S. Zoeckler, M. Jerkovic, J. F. M. Egberts, J. C. J. Stiekema, R. Berberich, F. Abedinpour
Publikováno v:
Age and ageing. 23(6)
A multicentre, double-blind, randomized study was performed in 179 patients with acute ischaemic stroke resulting in limb paresis. The purpose was to compare the safety and efficacy of Org 10172 (1250 anti-Xa Units s.c. once daily) and heparin sodium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::107cac34326aaefd08787ce3f8158041
https://pubmed.ncbi.nlm.nih.gov/9231947
https://pubmed.ncbi.nlm.nih.gov/9231947
Autor:
Adam F. Cohen, J. C. J. Stiekema, A C de Boer, Douwe D. Breimer, F. J. Kasper, J. M. Kroon, G. Dooijewaard, Cornelis Kluft
Publikováno v:
Thrombosis and haemostasis, 5, 68, 550-555
SummaryThe effects of heparin (5,000 IU i.v.) and the low molecular weight heparinoid Org 10172 (Orgaran®) (3,250 anti-Xa units i. v.) on components of the fibrinolytic system were studied in two double-blind, randomised, placebo-controlled, cross-o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25fe018286d6604710b09feadd93a194
http://resolver.tudelft.nl/uuid:01bc38cc-d9b1-4f93-84af-c41893c19572
http://resolver.tudelft.nl/uuid:01bc38cc-d9b1-4f93-84af-c41893c19572
1. We have investigated the effect of repeated s.c. Org 10172 (a low molecular weight heparinoid; Lomoparan) treatment (1000 anti-Xa units twice daily for 5 days) on antipyrine (500 mg orally) metabolism, and the effect of enzyme induction by pentoba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0ccc2a5064efad4096c257c8c9ada77
https://europepmc.org/articles/PMC1368488/
https://europepmc.org/articles/PMC1368488/
Autor:
J. C. J. Stiekema, M. G. Hanna, H. Breitz, A. X. Erdi, Y. E. Erdi, M. Sarfaraz, Barry W. Wessels, E. Yorke, I. Fand
Publikováno v:
Journal of Immunotherapy. 16:168
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e06f87d838ab144056b8e70fe62453d4
https://doi.org/10.1097/00002371-199408000-00090
https://doi.org/10.1097/00002371-199408000-00090
Autor:
H. Brink, F. Derkx, H. Kolstee, P. Merkus, J. Smits, A. Man in 't Veld, M. Schslekamp, C. T. Postma, W. H. L. Hoefnagels, Th. Thien, L. M. A. B. van Bortel, R. O. B. Böhm, J. M. V. Mooy, P. M. H. Schiffers, K. H. Rahn, A. J. M. Donker, A. Frydman, F. J. H. van Leerdam, P. M. J. H. de Vries, P. L. Oe, P. C. Chang, S. van Veen, P. Vermey, P. van Brummelen, J. Molema, J. -W. J. Lammers, H. Th. M. Folgering, C. L. A. van Herwaarden, A. de Boer, J. C. J. Stiekema, M. Danhof, J. K. Boei jinga, D. D. Breimer, G. J. Blauw, P. A. van Zwieten, C. J. Doorenbos, M. R. Daha, W. A. J. J. Hermans, M. T. I. W. Schüsler-van Hees, F. W. H. M. Merkus, H. G. J. Oldenhof, M. de Jong, A. Steenhoek, R. Janknegt, J. H. Koelman, M. J. Nube, C. Franssen, H. Wollersheim, B. Th. Veering, A. G. L. Burm, J. W. van Kleef, P. J. Hennis, Joh Spierdijk, J. G. Bovill, L. T. M. Breimer, E. A. de Bruijn, J. Schouten, P. Smits, A. van 't Laar, M. A. van Baak, F. Koene, F. T. J. Verstappen, J. A. van der Krogt, P. van Brumelen
Publikováno v:
Pharmaceutisch Weekblad. 9:187-192
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d179e92c0de2132793c062ebb67f4d4f
https://doi.org/10.1007/bf01967540
https://doi.org/10.1007/bf01967540
Autor:
F. A. van den Ouweland, P. C. Eenhoorn, Y. Tan, F. W. J. Gribnau, A. van Brupgen, P. A. de Graeff, E. W. van den Toren, W. H. van Gilst, H. Wesseling, K. I. Lie, C. T. Postula, W. B. L. Hoefnagels, Th. de Boo, Th. Thien, E. S. Boon, C. G. Goyskes, P. Boor, B. A. M. van Schalk, C. Abma, T. R. J. A. Frijns, J. Wamer, L. D. Elving, E. de Nobel, H. Mattie, C. van Gulpen, J-W. J. Lammers, P. Minette, P. J. Barnes, R. C. Jongejan, J. C. de Jongste, H. C. Raatgeep, I. L. Bonta, K. F. Kerrebijn, M. J. Mol, A. F. Stalenhoef, P. M. Stuyt, A. van 't Laar, A. A. M. Ermens, M. Schoester, J. Lindemans, J. Abels, M. A. van Baak, J. M. V. Mooij, P. M. H. Schiffers, J. F. M. Wetzels, J. D. v. Berqeyk, F. H. J. A. v. Heusden, F. Th. M. Huysmans, A. J. Hoitsma, R. A. P. Koene, H. M. L. Jansen, F. G. M. Russel, A. C. Wouterse, C. A. M. van Ginneken, Y. W. A. v. d. Pol, E. G. E. de Vries, J. Greidanus, N. H. Mulder, D. Th. Sleijfer, P. H. B. Willemse, D. R. A. Uges, P. A. B. M. Smits, J. W. Louwerenburg, J. H. Kingma, F. N. IJdenberg, F. G. J. Poelma, R. Breŝ, J. J. Tukker, H. P. Remmert, M. Olling, W. Slob, W. van der Giesen, A. G. Rauws, E. A. Runhaar, J. P. Neijt, J. J. M. Holthuis, D. de Vos, J J Tukker, F G J Poelma, H. H. W. Thijssen, K. Hamulyák, C. Franssen, H. Wollersheim, R. W. M. M. Jansen, H. J. J. van Lier, W. H. L. Hoefnagels, C. Grgen, M-A. Horan, Z. A. R. Oomerjee, D. D. Breimer, C. F. A. van Bezooijen, H. J. Keizer, F. J. Cleton, E. A. de Bruijn, U. R. Tiaden, A. de Boer, J. C. J. Stiekema, M. Danhof
Publikováno v:
Pharmaceutisch Weekblad. 10:178-184
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2b9f9514cb9f26f9956005c8dcb5f7f
https://doi.org/10.1007/bf01959428
https://doi.org/10.1007/bf01959428